Over the next couple of weeks, John and David will be reviewing their real-money 10-Bagger portfolio. In this video, they take a closer look at MAKO Surgical.
MAKO started out very strong in the portfolio. But a series of poor earnings reports has caused the stock to fall. It's down just under 40% in our portfolio. The selloff looks well overdone, however. There's no denying growth has slowed -- but not enough to warrant that far a fall. Like Intuitive Surgical before it, MAKO's next challenge is convincing larger hospital systems that robotic surgery is an evolution, not a revolution.
So far, it's making some progress. Knee and hip replacement surgeries will grow over time. So as that message gets out, MAKO is well-positioned against implant makers such as Stryker, Johnson & Johnson, and Zimmer Holdings to meet that demand. Based on the long-term outlook and the attractiveness of its shares, John and David see MAKO as worth buying today and have put their money where their mouths are by purchasing more MAKO for the portfolio.
Not everyone agrees with John and David's analysis on MAKO Surgical. The recent market sell-off of its shares has many wondering whether the potential growth prospects of the robotic surgery company make it a buy today or a stock to stay away from. Read our premium report to get more details on MAKO's story. Click here to access it now.
The article Portfolio Review: MAKO Surgical originally appeared on Fool.com.
David Meier and John Reeves have no positions in the stocks mentioned above. The Motley Fool owns shares of Intuitive Surgical, Johnson & Johnson, MAKO Surgical, and Zimmer Holdings. Motley Fool newsletter services recommend Intuitive Surgical, Johnson & Johnson, and MAKO Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.